Official Title
The Use of Ivermectin In the Treatment of COVID 19 Patients
Brief Summary

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Detailed Description

the study will compare the effect of ivermectin in comaprison and addition to the standard
mode of care for the COVID 19 patients

Unknown status
COVID19

Drug: Ivermectin

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
Other Name: hydroxychloroquine

Eligibility Criteria

Inclusion Criteria:

- Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral
RNA swap

Exclusion Criteria:

- Contraindications for the drug: hypersensitivity.

- Any medications with possible drug interactions.

- Severe cases.

- Any malignant condition.

- Pregnant females.

- Breast feeding females.

- Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to
potential severe drug interaction.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Egypt
Locations

isolation and referal hospitals for COVID 19 patients
Cairo, Egypt

Investigator: ehab ah kamal, MD
Contact: 01006162663

Contacts

ehab ah kamal, MD
01006162663
ehabkamal2011@hotmail.com

noha mo asem, MD

houssam ho masoud, MD, Study Director
COVID sceintific comittee ministry of health and population

Ministry of Health and Population, Egypt
NCT Number
MeSH Terms
COVID-19
Hydroxychloroquine
Ivermectin